Maxcyte Proposed AIM cancellation to focus on sole listing on NASDAQ, another body blow for the Casino
The proposed cancellation of Maxcyte’s (MXCT) listing on AIM, with MaxCyte moving to a sole listing on the NASDAQ in New York is another body blow to the credibility of AIM and U.K. markets. This is not a bad company going bust but a good company saying that AIM is not fit for purpose.

